Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Tobin Schilke Insider Profile
4 Followers
Tobin Schilke, CFO at Achaogen, holds 193.67K shares in Revance Therapeutics (Ticker: RVNC), holds 47.75K shares in Achaogen (Ticker: AKAOQ).
Profitable Transactions
4 out of 4 Profitable Transactions
Average Return
+54.20%
Average return per transaction
Time Frame
Compare to
Insider Roles
CFO
Roles that Tobin Schilke holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Sell
Date:May 16, 2023 - May 16, 2024
Return:+90.50%
The most profitable trade made by Tobin Schilke
Tobin Schilke's Trading History
Achaogen
Jun 28, 2018
―
Uninformative Buy
―
$1.19K
Revance Therapeutics
Jul 02, 2024
CFO
Uninformative Buy
2.18K
$743.68K
List of latest transactions for each holding click on a transaction to see Tobin Schilke's performance on stock
You May Also Like
Tobin Schilke insider profile FAQ
What is the percentage of profitable transactions made by Tobin Schilke?
The percentage of profitable transactions made by Tobin Schilke is 100%.
What is the average return per transaction made by Tobin Schilke?
The average return per transaction made by Tobin Schilke is 54.20%.
What stocks does Tobin Schilke hold?
Tobin Schilke holds: AKAOQ, RVNC stocks.
What was Tobin Schilke’s latest transaction?
Tobin Schilke latest transaction was an Uninformative Buy of $2.18K.
What was Tobin Schilke's most profitable transaction?
Tobin Schilke’s most profitable transaction was an Informative Sell of RVNC stock on May 16, 2023. The return on the trade was 90.50%.
What is Tobin Schilke's role in Achaogen?
Tobin Schilke's role in Achaogen is CFO.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.